EMMA 2016 | What are the current treatment options for Waldenström’s macroglobulinemia?
Stathis Kastritis, MD from the University of Athens School of Medicine, Athens, Greece speaks about the current treatment options for Waldenström’s macroglobulinemia (WM) at the 2016 European Multiple Myeloma Academy (EMMA) in Madrid, Spain. This is a rare form of non-Hodgkin lymphoma (NHL). Over the past few years, more and more treatment options have been identified, including monoclonal antibodies and targeted therapies, such as proteasome inhibitors and PDK inhibitors. There are currently many options for patients and choose treatment based on the characteristics of the disease and the patient. The majority of treatment is based on monoclonal antibodies like rituximab in combination with chemotherapy; however, ibrutinib is a PDK1 inhibitor and has has demonstrated positive results in patients with relapsed disease, and even as a frontline therapy for some patients.
This programme has been supported by Celgene and Amgen through an unrestricted educational grant to the Video Journal of Hematological Oncology.
